Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (UPECLIN)
- Development stage
- Unknown
- Lead developer
- UPECLIN HC FM Botucatu UNesp
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subcutaneous, Topical
01
Overview
Autologous adipose-derived mesenchymal stem cell (MSC) therapy developed by UPECLIN HC FM Botucatu Unesp for the treatment of critical limb ischemia (CLI) and associated lower limb ulcers. The therapy involves extracting adipose tissue from the patient's abdomen, expanding the mesenchymal stem cells in a specialized cell processing center, and re-administering them to the patient. The administration protocol includes perilesional subcutaneous injections and the application of a personalized biological dressing containing the expanded cells. The treatment aims to stimulate angiogenesis and provide immunomodulatory effects to promote the healing of chronic arterial ulcers in patients who are not candidates for conventional revascularization procedures.
- Other names
- CELULAS TRONCOautologous mesenchymal stem cell therapyadipose-derived mesenchymal stem cellsAD-MSCs
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (UPECLIN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (UPECLIN).